Appili Therapeutics Inc.
APLI.TO
TSX
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -77.94% | 9.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -77.94% | 9.27% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -77.94% | 9.27% | |||
| SG&A Expenses | 287.95% | -55.45% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 250.99% | -41.37% | |||
| Operating Income | -303.73% | 45.43% | |||
| Income Before Tax | -7.55% | 2.70% | |||
| Income Tax Expenses | 321.43% | -72.44% | |||
| Earnings from Continuing Operations | -10.76% | 5.15% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -10.76% | 5.15% | |||
| EBIT | -303.73% | 45.43% | |||
| EBITDA | -304.82% | 45.47% | |||
| EPS Basic | -30.19% | 10.17% | |||
| Normalized Basic EPS | -24.24% | 8.33% | |||
| EPS Diluted | -30.19% | 10.17% | |||
| Normalized Diluted EPS | -24.24% | 8.33% | |||
| Average Basic Shares Outstanding | -14.48% | 5.85% | |||
| Average Diluted Shares Outstanding | -14.48% | 5.85% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||